Back to homepage

Respiratory

Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors?

Authors: Francesco Menzella MD, Mirella Biava Msc, Diego Bagnasco MD, PhD, Carla Galeone Msc, Anna Simonazzi MD, Patrizia Ruggiero Msc, Nicola Facciolongo MD

This article is an indirect comparison among literature data, especially between OCS reduction studies (ZONDA-SIRIUS) and pivotal studies (SIROCCO-MENSA), evaluating whether the clinical efficacy and the steroid-sparing effect of benralizumab may represent an advantage over other compounds. This data could help the clinician in the decision process of treatment choice, within the different available therapeutic options for eosinophilic refractory severe asthma.

More▸

Agents to treat BRAF-mutant lung cancer

Authors: Jean G Bustamante Alvarez MD, MS, Gregory A Otterson MD

Keywords: dabrafenib, immunotherapy, lung neoplasm, protooncogene protein B-raf, trametinib. Citation: Bustamante Alvarez JG, Otterson GA. Agents to treat BRAF-mutant lung cancer. Drugs in Context 2019; 8: 212566. DOI: 10.7573/dic.212566 Contributions: Both authors contributed equally to the preparation of this review.

More▸

Severe refractory asthma: current treatment options and ongoing research

Authors: Francesco Menzella MD, Francesca Bertolini MSc, PhD, Mirella Biava MSc, Carla Galeone MSc, Chiara Scelfo MD, Marco Caminati MD

In this review, the different biological options available for the treatment of severe refractory asthma, their mechanism of action, and the overlapping aspects of their usage in clinical practice are discussed.

More▸

Sublingual allergen immunotherapy for respiratory allergy: a systematic review

Authors: Carlos Blanco MD, PhD, Raphaelle Bazire MD, Laura Argiz MD, Jenaro Hernández-Peña MD, PhD

This systematic review provides complete and updated information on efficacy and safety of sublingual immunotherapy (SLIT) formulations for the treatment of allergic respiratory diseases (ARDs).

More▸

Satisfaction and quality of life of allergic patients following sublingual five-grass pollen tablet immunotherapy in Spain

Authors: Darío Antolín-Amerigo, Isabel A Tabar, Maria del Mar Fernández-Nieto, Anna M Callejo-Melgosa, Francisco J Muñoz-Bellido, José C Martínez-Alonso, Jorge D Méndez-Alcalde, Marta Reche, Ana Rodríguez-Trabado, Ana Rosado-Ingelmo, Alicia Alonso-Gómez, Rosa Blanco-González, José A Alvarez-Fernandez, Isabel Botella, Ana Valls, Mercedes Cimarra, Carlos Blanco

This trial sought to determine the satisfaction and health-related quality of life (HRQoL) of patients undergoing five-grass pollen tablet treatment.

More▸